HOME ·

02617.HK

TRANSTHERA-B (02617.HK) HKEX approves H-share full circulation of 44.97m shares
Tags：
TRANSTHERA-B02617.HKH-share full circulation
2026-11-01
TransThera-B (02617.HK): Yochanra® begins nationwide sales
Tags：
TRANSTHERA-B02617.HKInnovative Drugs
2026-10-22
TRANSTHERA-B (02617.HK): Tinengotinib Included in CSCO Guidelines for Biliary Tract Malignancies (2026)
Tags：
TRANSTHERA-B02617.HKR&D Progress
2026-09-18
TRANSTHERA-B(02617.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 95.47 million, loss narrowed by 22.3% YoY
Tags：
TRANSTHERA-B02617.HK
2026-08-27
TRANSTHERA-B (02617.HK): Class 1 New Drug Jientai (Tiengotinib Tablets) Receives Conditional NMPA Approval for FGFR2 Fusion Advanced Cholangiocarcinoma
Tags：
TRANSTHERA-B02617.HKNMPA Approval
2026-08-06
TRANSTHERA-B (02617.HK) plans to issue in total 3.84 million shares by placement, with estimated net proceeds of HKD 152.13 million
Tags：
TRANSTHERA-B02617.HKshare placement
2026-05-19
TRANSTHERA-B (02617.HK): Clinical Data of Core Product Tiengrtinib Published in Nature Communications
Tags：
TRANSTHERA-B02617.HKclinical development
2026-05-17
TransThera Sciences-B (02617.HK): Successfully Completes H-Share Placement, Raising Approximately HK$190 Million to Fund Core Product R&D
Tags：
TRANSTHERA-B02617.HKH-share placement
2026-01-20